MedTrace Logo

Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance

NCT01471990 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-08-29

No results posted yet for this study

Summary

The purpose of this study is to examine and compare the effect of pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) on intracranial arteries and neuronal activity in patients with migraine without aura using a high resolution magnetic resonance imaging (MRI), including MR angiography (MRA) and functional MRI (fMRI).

MRA will be used to detect changes in intracranial artery circumferences before and after PACAP38 and VIP.

fMRI will be used oo detect changes in blood-oxygenation-level-dependent-signal (BOLD-signal).

PACAP38 but not VIP induces migraine like attacks in migraine patients. The migraine specific drug sumatriptan will be given to relieve pain and the effect will also be registered using MRA and fMRI.

Conditions

  • Migraine Without Aura

Interventions

DRUG

Pituitary Adenylate Cyclase-Activating Polypeptide-38

10 pmol/kg/min over 20 mins

DRUG

Vasoactive Intestinal Peptide

8 pmol/kg/min over 20 mins

Sponsors & Collaborators

  • Bispebjerg Hospital

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    collaborator OTHER

  • Lundbeck Foundation

    collaborator OTHER

  • Cool Sorption Foundation of 1988

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    lead OTHER

Principal Investigators

  • Faisal Amin, M.D. · Danish Headache Centre and Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01471990 on ClinicalTrials.gov